{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:25:39Z","timestamp":1782980739209,"version":"3.54.5"},"reference-count":45,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and aims<\/jats:title><jats:p>An investigation of 24 weeks of extended\u2010release buprenorphine (BUP\u2010XR; Sublocade\u00ae) treatment for adults with opioid use disorder (OUD). Study aims were to characterise variations in clinical response, investigate personal factors influencing BUP\u2010XR experience and identify opportunities to tailor treatment interventions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>A convergent parallel mixed\u2010methods evaluation embedded in a five\u2010centre, phase 3, randomised controlled trial of BUP\u2010XR versus daily oral methadone or sublingual buprenorphine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Four of five National Health Service addictions treatment clinics in England and Scotland from the trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Participants were recruited after they completed the 24\u2010week endpoint. Forty\u2010nine participants (31%) from the trial completed the qualitative interview.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>Three outcome measures from the trial's dataset were used descriptively: (1) fortnightly clinic visit administered TimeLine Follow\u2010Back interview and urine drug screen data on use of non\u2010medical opioids, cocaine and benzodiazepines; (2) the frequency version of the 11\u2010item Craving Experience Questionnaire administered at baseline and endpoint; and (3) the Structured Clinical Interview for DSM\u20105 disorders for diagnosis of early OUD and cocaine use disorder (CUD) remission. Data visualisation (by heatmap) identified drug use response sub\u2010groups. A topic\u2010guided, semi\u2010structured qualitative interview was analysed by Interactive Categorisation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>Three response sub\u2010groups were identified: Group 1 [14 (28.5%) of 49 participants] had the highest level of response, characterised by continuous abstinence from opioids, cocaine and benzodiazepines, improvements in craving control and mental and physical health in the majority, and a high level of remission and satisfaction with care; Group 2 [14 (28.5%) of 49 participants] had the next level of response, characterised by continuous abstinence from opioids, but some with opioid craving and some with compensatory use of cocaine and benzodiazepine to cope with anxiety and stress; Group 3 [21 (43.0%) of 49 participants] were not continuously abstinent from opioids during follow\u2010up, the majority had dual OUD and CUD at trial enrolment, some reported breakthrough opioid withdrawal symptoms during follow\u2010up, the majority reported improvements in mental health, but many reported opioid and cocaine cravings and compensatory use of cocaine and benzodiazepines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There appears to be variation in response and experience of extended\u2010release buprenorphine during the first six months of treatment, depending on substance use and physical health. This highlights the need for tailored treatment plans based on differing individual needs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/add.70106","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T03:59:35Z","timestamp":1750391975000},"page":"2055-2066","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Extended\u2010release buprenorphine treatment for opioid use disorder: A mixed\u2010methods study of response and experience"],"prefix":"10.1111","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9137-5005","authenticated-orcid":false,"given":"Natalie","family":"Lowry","sequence":"first","affiliation":[{"name":"Addictions Department School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London  London UK"},{"name":"Lambeth Drug and Alcohol Service South London and Maudsley NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McKechnie","sequence":"additional","affiliation":[{"name":"Dundee Drug and Alcohol Recovery Service Dundee Health and Social Care Partnership  Scotland UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Day","sequence":"additional","affiliation":[{"name":"Solihull Integrated Addiction Service Birmingham and Solihull Mental Health NHS Foundation Trust  Birmingham UK"},{"name":"Institute for Mental Health, School of Psychology Birmingham University  Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilish","family":"Gilvarry","sequence":"additional","affiliation":[{"name":"Newcastle Treatment and Recovery Cumbria, Northumberland, Tyne and Wear NHS Foundation  Newcastle Upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Cowden","sequence":"additional","affiliation":[{"name":"Dundee Drug and Alcohol Recovery Service Dundee Health and Social Care Partnership  Scotland UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Evans","sequence":"additional","affiliation":[{"name":"School of Health Sciences Bangor University  Wales UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Locke","sequence":"additional","affiliation":[{"name":"Newcastle Treatment and Recovery Cumbria, Northumberland, Tyne and Wear NHS Foundation  Newcastle Upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbie","family":"Murray","sequence":"additional","affiliation":[{"name":"Newcastle Treatment and Recovery Cumbria, Northumberland, Tyne and Wear NHS Foundation  Newcastle Upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Vanderwaal","sequence":"additional","affiliation":[{"name":"Lambeth Drug and Alcohol Service South London and Maudsley NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Johnstone","sequence":"additional","affiliation":[{"name":"Dundee Drug and Alcohol Recovery Service Dundee Health and Social Care Partnership  Scotland UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Hoare","sequence":"additional","affiliation":[{"name":"School of Health Sciences Bangor University  Wales UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kelleher","sequence":"additional","affiliation":[{"name":"Addictions Department School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London  London UK"},{"name":"Lambeth Drug and Alcohol Service South London and Maudsley NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Mitcheson","sequence":"additional","affiliation":[{"name":"Addictions Department School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London  London UK"},{"name":"Lambeth Drug and Alcohol Service South London and Maudsley NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1307-2498","authenticated-orcid":false,"given":"John","family":"Marsden","sequence":"additional","affiliation":[{"name":"Addictions Department School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London  London UK"},{"name":"Lambeth Drug and Alcohol Service South London and Maudsley NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Public Heath England.Part 1: Introducing opioid substitution treatment (OST).2021."},{"key":"e_1_2_10_3_1","unstructured":"Office for Health Improvement & Disparities.Adult substance misuse treatment statistics 2022 to 2023: Report2023."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy12050152"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2012.03971.x"},{"key":"e_1_2_10_6_1","unstructured":"FelberbaumM.FDA approves first once\u2010monthly buprenorphine injection a medication\u2010assisted treatment option for opioid use disorder: U.s. food and drug administration.2017.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-once-monthly-buprenorphine-injection-medication-assisted-treatment-option-opioid"},{"key":"e_1_2_10_7_1","unstructured":"Camurus.Buvidal\u00ae weekly and Buvidal\u00ae monthly (CAM2038) approved in Australia as the first long\u2010acting treatment of opioid dependence.2018.https:\/\/www.camurus.com\/media\/press-releases\/2018\/buvidal-weekly-and-buvidal-monthly-cam2038-approved-in-australia-as-the-first-long-acting-treatment-of-opioid-dependence\/"},{"key":"e_1_2_10_8_1","unstructured":"Agency EM.Buvidal2018.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/buvidal#:~:text=Other%20information%20about%20Buvidal EU%20on%2020%20November%202018"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102311"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06595-0"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-088617"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104221"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-024-00984-1"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/00914509221140959"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2023.2244064"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-023-00551-0"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2022.104174"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780198802082.001.0001","volume-title":"A practical guide to using qualitative research with randomized controlled trials","author":"O'Cathain A","year":"2018"},{"key":"e_1_2_10_19_1","volume-title":"Research design: qualitative, quantitative, and mixed methods approaches","author":"Creswell JW","year":"2017"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067194"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/08874417.2013.11645667"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.03.018"},{"key":"e_1_2_10_23_1","volume-title":"Timeline followback user's guide: a calendar method for assessing alcohol and drug use","author":"Sobell L","year":"1996"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12472"},{"key":"e_1_2_10_25_1","unstructured":"FirstMB WilliamsJB KargRS SpitzerRL.Structured clinical interview for DSM\u20105 disorders. Clinician version (SCID\u20105\u2010CV).2015."},{"key":"e_1_2_10_26_1","first-page":"541","volume-title":"Best practices for mixed methods research in the health sciences","author":"Creswell JW","year":"2011"},{"key":"e_1_2_10_27_1","unstructured":"Lumivero.NVivo. Version 14 ed2023."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13314"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15259"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.2307\/2137284"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.9041"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1052"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-090736"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpra.2011.11.001"},{"issue":"1","key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/00981380902958486","article-title":"Menopause symptom attribution among mildlife women in methadone treatment","volume":"49","author":"Tuchman E","year":"2010","journal-title":"Soc Work Health Care"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-023-01185-4"},{"key":"e_1_2_10_37_1","unstructured":"VA Pharmacy Benefits Management Services and the National Formulary Committee in Collaboration with the VHA National Office of Pain Management OSaPP. Buprenorphine for the Management of Chronic Pain In: Document NG editor.2024."},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.8361"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.2147\/PRBM.S44762"},{"key":"e_1_2_10_40_1","unstructured":"National Institute for health and care excellence.Menopause [a] cognitive behavioural therapy2024."},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2017.10.009"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15405"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.2.340"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-021-00229-7"},{"key":"e_1_2_10_45_1","volume-title":"AMIA annual symposium proceedings","author":"Blackley SV","year":"2021"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104748"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.70106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T05:17:46Z","timestamp":1757654266000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.70106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/add.70106"],"URL":"https:\/\/doi.org\/10.1111\/add.70106","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"2024-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}